Amylyx Pharmaceuticals Return on Equity

Amylyx Pharmaceuticals (AMLX) currently reports a ROE of -21.65%. That is below the sector sector average of 11.67%. Use the charts on this page to explore Amylyx Pharmaceuticals's ROE history and peer comparisons.

Amylyx Pharmaceuticals's ROE of -21.65% is lower than the its sector sector average of 11.67%. That is roughly 285.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Amylyx Pharmaceuticals's current -21.65% should be judged against industry norms (sector average: 11.67%) and against AMLX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -21.65%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.67%. From there, open related valuation or income-statement pages for Amylyx Pharmaceuticals, and consider following AMLX for alerts when major investors trade the stock.